INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic multisystem disorder which mainly results from the lack of functional Tsc1-Tsc2 complex due to mutations in TSC1 or TSC2 genes encoding hamartin and tuberin respectively, and belongs to a group of neurocutaneous syndromes together with Sturge-Weber syndrome, von HippelLindau disease, and neurofibromatosis [1,2].
Pathologically, TSC is defined as a disorder of cell migration, proliferation and differentiation.
[3] The incidence rates of TSC were estimated to be 1 /6,000 and 1 /10,000 [1, 4, 5] among live births; however previous studies [2, 6] reported that there are undetected mild TSC cases and this makes the true incidence likely to be higher.
Mutations in TSC1or TSC2 genes were found in approximately 85% of patients with TSC [7, 8] . The role of TSC1-TSC2 protein complex is an upstream regulator of mammalian target of rapamycin (mTOR), any disruption of this function results in over activation of mTOR and dysregulated growth control, hence explaining the fundamental pathological mechanism of TSC disorder [1, 9] .
The clinical diagnosis of TSC is challenging as the disease is highly variable in clinical presentation, findings, and its manifestations continue to develop over the lifetime of the affected individuals and can vary widely between even closely related individuals [10] . In the recommendations of the 2012 international TSC consensus conference for TSC diagnostic criteria update [10] 
Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic neurocutaneous disorder, with heterogeneous manifestations. We aimed to review the clinical presentation of TSC and its association with epilepsy among Saudi population. This was a retrospective chart review study of 88 patients diagnosed with TSC with or without epilepsy. In 38.6% of patients, symptoms began before 1 year of age. The most frequent initial manifestations of TSC were new onset of seizures (68.2%), skin manifestations (46.6%) and development delay (23.9%). During the evolution of the disease 65.9% had epilepsy, 17% facial angiofibromas, 13.6% Shagreen patch, 18.2% heart rhabdomyomas and 12.5% retinal hamartomas. The genetic study for TSC diagnosis was done for 44 patients, 42 (95,4%) of them were genetically confirmed, for whom 13 patients had TSC1 mutation (29.5%), 29 patients were carrying TSC2 gene mutation (65.9%), Genetic test for TSC 1 and TSC 2 were negative for 2 patients (4.5%) despite positive gene mutation in their relative with TSC. The most common manifestations were central nervous system (predominantly epilepsy) and dermatological manifestations. Most of the patients develop epilepsy with multiple seizure types. TSC 2 mutation is more common than TSC 1 mutation. structural abnormalities and pathological changes were thought to be responsible for TSC patients neurological phenotype; however, current studies have proposed that subtler microscopic changes like aberrant white matter connectivity, which cannot be envisioned with regular MR imaging techniques, play a role in causing epilepsy, ASD, behavioral problems and cognitive deficits [13] . Previous studies reported that epilepsy is the most common and troublesome symptom in TSC patients, seen in 80-90% of the affected individuals, often refractory to treatment and a significant source of morbidity and mortality [14] . 
METHODS
We included all patients (88) 
RESULTS:
A total of 88 patients with confirmed TSC diagnosis were included in the current study.
The cohort had a mean age of 16.56±14.21, the highest percentage of them (23.9%) were in the age group of 11-14 years old followed by 22.7% aged 7-10 years old. (Table 1 ).
The highest percentage (38.6%) of the participants had age of onset less than one year for the first time of symptoms presentation, followed by 30.7%, 15.9%, and 14.8% at the age of 1-5, 6-10, and > 10 years, respectively.
( Fig. 1) Seizure was the highest prevalent symptom of TSC among the studied cohort accounting at 68.2% followed by skin manifestations at 46.6%
and development delay at 23.9% (Table 2) .
Seizures and skin manifestations were highly prevalent in males compared to females (69.6% and 48.2% versus 65.65% and 43.8%, respectively). On the other hand, the prevalence of global development delay was higher in females compared to males (25% and 23.2%, respectively). The prevalence of other manifestations including delayed learning, ADHD, and autism, were as following: 11.4%, 11.4%, 6.8%, and 9.1% respectively ( Table 3 ).
The patients were categorized according to their age groups into two groups: <14 (children) and ≥14 years old (adults). It was observed that the prevalence of skin manifestations, development delay, ADAH and autism was higher in children compared to adults (48%, 29%,12% and 10% versus 24%, 17%, 0% and 8%, respectively) ( Table 7) .
The results of psychological evaluation showed that, among the studied TSC cohort, the prevalence of ADHD and autism was 26.1%
and 17%, respectively, being higher in patients aged <14 at 28.85% and 19.23% compared to those aged ≥14 at 22.22% and 13.89%
respectively, but the difference was nonsignificant in both cases (P <0.23 and <0.25, 
DISCUSSION
To the best of our knowledge, the current study represents the first study reporting the clinical spectrum and epilepsy among TSC patients in Saudi Arabia and the whole Gulf Cooperation Council (GCC) countries.
It might contribute towards a better understanding of the disease complexity and its management in the community setting. We reported comprehensive data on known TSC manifestations, including their prevalence, age of onset and their differences by age, gender and the time of their presentations.
In contrast to what had been previously reported in the literature [7, 8] , the current study has a higher percentage of patients with genetically confirmed TSC genes (TSC1 and TSC2) mutations (85% versus 95,4%). TSC2 mutation was higher than TSC1, a finding which is in line with Dabora SL et al study [20] . On the other hand, the prevalence of Angiomyofibroma reported in the current study was higher compared to that reported by Rubilar C. et al at 26.1% and 16.7%, respectively, while a slightly higher prevalence of renal cyst was reported compared to the same study (14.8% and 14.3%) [21] .
In majority of the patients the initial manifestations were detected before the first year of life, which is in line with what is reported in the literature [22] . In most patients the onset of seizure was earlier than 1 year of age which are rarely observed in patients without this disease [10] , therefore, the lower prevalence reported in our study emphasize the importance of addition to early onset, In accordance with the literature [20] , our results showed that ungual fibromas are less common compared to some other TSC skin findings, with a higher frequency in older patients, and its later onset, typically in the second decade or later [24] , is the cause of the greater frequency in adults. Thus, their usefulness in diagnosis is usually limited to adolescents and adults. The current study result in regards to a significant higher prevalence of facial angiofibroma in adults is in contrast to 
CONCLUSION
The study shows the nature of TSC among Saudi population, with patients presenting with a broad spectrum of manifestations, the prevalence of which was estimated and the most common manifestations were central nervous system (predominantly epilepsy) and dermatological manifestations, the estimated prevalence was mostly lower compared to the literature. Most patients develop epilepsy with multiple seizure types and they did not achieve seizure freedom however; most of them were controlled on 2-3 antiepileptic medications. 
